Published in Clin Rheumatol on March 06, 2007
Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep (2014) 0.96
Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis (2010) 0.95
Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther (2013) 0.94
Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. J Med Case Rep (2009) 0.84
Sarcoid-like granulomatosis in patients treated with anti-TNFα factors. A case report and review of the literature. Clin Rheumatol (2010) 0.84
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Translating co-stimulation blockade into clinical practice. Arthritis Res Ther (2008) 0.79
Update on bioagent therapy in sarcoidosis. F1000 Med Rep (2010) 0.77
Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature. Clin Rheumatol (2010) 0.76
Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature. Ann Dermatol (2017) 0.75
Lung sarcoidosis in etanercept treated rheumatoid arthritis patient: a case report and review of the literature. Case Rep Rheumatol (2014) 0.75
Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int (2010) 0.75
Certolizumab Pegol-Induced Folliculitis-Like Lichenoid Sarcoidosis in a Patient with Rheumatoid Arthritis. Case Rep Dermatol (2017) 0.75
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest (2003) 1.61
Pulmonary sarcoidosis. Allergy (2005) 1.59
Treatment of sarcoidosis with infliximab. Chest (2005) 1.43
The cytokine network in sarcoidosis and its clinical relevance. J Intern Med (2003) 1.27
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum (2006) 1.26
Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum (2005) 1.18
Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl (2005) 1.14
Development of sarcoidosis during etanercept therapy. Arthritis Rheum (2006) 1.13
Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum (2005) 1.03
The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis (2004) 0.88
A possible association of rheumatoid arthritis and sarcoidosis. Chest (1989) 0.86
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum (2002) 5.57
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis (2011) 2.13
EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis (2011) 2.04
Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol (2008) 2.01
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther (2005) 1.96
Detection of antinuclear antibodies by automated indirect immunofluorescence analysis. Clin Chim Acta (2012) 1.88
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem (2007) 1.37
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.37
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis (2009) 1.29
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat (2006) 1.26
Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol (2006) 1.13
Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev (2012) 1.07
A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis (2010) 1.05
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther (2006) 1.05
Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol (2013) 1.04
Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum (2007) 1.01
Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Musculoskeletal Care (2009) 0.98
Left atrial myxoma on FDG-PET/CT. Clin Nucl Med (2013) 0.92
Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford) (2012) 0.92
Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay. Autoimmun Rev (2011) 0.91
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther (2010) 0.91
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol (2008) 0.90
Value-added reporting of antinuclear antibody testing by automated indirect immunofluorescence analysis. Clin Chem Lab Med (2014) 0.89
Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Ann Rheum Dis (2010) 0.88
Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget's Disease of Bone. Calcif Tissue Int (2008) 0.87
Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clin Ther (2008) 0.86
What does it mean to grow up with juvenile idiopathic arthritis? A qualitative study on the perspectives of patients. Clin Rheumatol (2010) 0.86
Transfer from paediatric rheumatology to the adult rheumatology setting: experiences and expectations of young adults with juvenile idiopathic arthritis. Clin Rheumatol (2012) 0.86
Attitudes of rheumatology practitioners toward transition and transfer from pediatric to adult healthcare. Rheumatol Int (2011) 0.85
Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol (2011) 0.85
Methotrexate: the gold standard without standardisation. Ann Rheum Dis (2009) 0.83
The association of illness perceptions with physical and mental health in systemic sclerosis patients: an exploratory study. Musculoskeletal Care (2011) 0.83
Clinical and serological evaluation of a novel CENP-A peptide based ELISA. Arthritis Res Ther (2010) 0.83
The epidemiology of rheumatoid arthritis in Kinshasa, Democratic Republic of Congo--a population-based study. Rheumatology (Oxford) (2012) 0.82
Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol (2004) 0.82
The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol (2012) 0.81
Provisional diagnostic criteria for polymyalgia rheumatica: moving beyond clinical intuition? Ann Rheum Dis (2012) 0.80
Hand radiological damage in systemic sclerosis: comparison with a control group and clinical and functional correlations. Semin Arthritis Rheum (2010) 0.80
Heterogeneous nuclear RNPs as targets of autoantibodies in systemic rheumatic diseases. Arthritis Rheum (2012) 0.80
Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria. Rheumatology (Oxford) (2009) 0.79
Anti-TNF therapy and malignancy in spondyloarthritis in the Leuven spondyloarthritis biologics cohort (BIOSPAR). Clin Exp Rheumatol (2013) 0.79
Translating co-stimulation blockade into clinical practice. Arthritis Res Ther (2008) 0.79
Anti-Golgi autoantibodies are not clinically associated with systemic autoimmune diseases. Ann Rheum Dis (2010) 0.79
Destructive dural ectasia of dorsal and lumbar spine with cauda equina syndrome in a patient with ankylosing spondylitis. Open Rheumatol J (2010) 0.78
A Review of Persuasive Principles in Mobile Apps for Chronic Arthritis Patients: Opportunities for Improvement. JMIR Mhealth Uhealth (2016) 0.78
Septic arthritis due to Staphylococcus warneri: a diagnostic challenge. Open Rheumatol J (2012) 0.77
Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. Rheumatol Int (2014) 0.77
A maximum difference scaling survey of barriers to intensive combination treatment strategies with glucocorticoids in early rheumatoid arthritis. Clin Rheumatol (2015) 0.77
Mechanical loading reduces inflammation-induced human osteocyte-to-osteoclast communication. Calcif Tissue Int (2015) 0.76
Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'. Arthritis Res Ther (2006) 0.75
The efficacy and safety of abatacept in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2010) 0.75
The optimal combination therapy for the treatment of early rheumatoid arthritis. Expert Opin Pharmacother (2015) 0.75
Rheumatoid arthritis: defining remission in patients with RA in clinical practice. Nat Rev Rheumatol (2012) 0.75
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. Arthritis Res Ther (2010) 0.75
Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. Eur J Gastroenterol Hepatol (2017) 0.75
Heterogeneous nuclear ribonucleoprotein h1, a novel nuclear autoantigen. Clin Chem (2009) 0.75
Association study of the platelet collagen receptor glycoprotein VI gene with rheumatoid arthritis. Clin Exp Rheumatol (2013) 0.75
Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. Value Health (2011) 0.75
Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis. Clin Rheumatol (2011) 0.75
PAS-positive macrophages--not always infection. Lancet (2011) 0.75
Antibodies to heterogeneous nuclear ribonucleoprotein H1 are directed to RNA recognition motif 3. Rheumatology (Oxford) (2011) 0.75
Unusual cervical spine involvement in psoriatic arthritis: a case series. Clin Rheumatol (2009) 0.75
Antibodies to hnRNPs in patients with a systemic rheumatic disease with no antibodies to extractable nuclear antigens or dsDNA. Rheumatology (Oxford) (2012) 0.75